{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:48:56Z","timestamp":1755218936175,"version":"3.43.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Cerebral lymphoma is a rare and aggressive brain tumor. It accounts for 1% of all non-Hodgkin\u2019s lymphomas (NHL) and 2% of all brain tumors. Untreated brain lymphoma has a very poor prognosis, with an overall life expectancy of around 1.5 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation:<\/jats:title>\n            <jats:p>The authors report the case of a 35-year-old patient, with no previous pathological history, who presented for 3 weeks with deafness and recently aggravated otalgia. In MRI, brain imaging revealed a formation initially suggestive of an aggressive meningioma, and the histological study of the operative specimen was in favor of a diffuse large-cell non-germ-center B NHL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical discussion:<\/jats:title>\n            <jats:p>Primary central nervous system lymphoma is an extra-nodal NHL localized to the brain, meninges, spinal cord, and eyes. In 90% of cases, these are diffuse large B-cell lymphomas, the other types being poorly characterized low-grade lymphomas, T-cell lymphomas, and Burkitt\u2019s lymphomas. MRI with gadolinium contrast is the gold standard for diagnosis which enhancement is homogeneous and well-limited, frequently associated with perilesional vascular edema. In T2-weighted sequences, there is a weak signal with restricted diffusion on diffusion-weighted imaging. The management of brain lymphoma is currently based on chemotherapy with high-dose methotrexate combined with the other agents, mainly rituximab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Cerebral lymphoma remains a non-negligible entity of central nervous system tumors, which can be confused with several other tumors, mainly glial and meningioma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ms9.0000000000001126","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T06:00:15Z","timestamp":1691733615000},"page":"5100-5104","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A cerebral lymphoma mimicking a meningioma: case report"],"prefix":"10.1097","volume":"85","author":[{"given":"Imane","family":"Joudar","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Mohammed First University"},{"name":"Department of Radiology, Mohammed VI University Hospital, Mohammed First University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siham","family":"Nasri","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Mohammed First University"},{"name":"Department of Radiology, Mohammed VI University Hospital, Mohammed First University"},{"name":"Faculty of Medicine and Pharmacy, Mohammed First University, LAMCESM, Oujda, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narjisse","family":"Aichouni","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Mohammed First University"},{"name":"Department of Radiology, Mohammed VI University Hospital, Mohammed First University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Kamaoui","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Mohammed First University"},{"name":"Department of Radiology, Mohammed VI University Hospital, Mohammed First University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Skiker","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Mohammed First University"},{"name":"Department of Radiology, Mohammed VI University Hospital, Mohammed First University"},{"name":"Faculty of Medicine and Pharmacy, Mohammed First University, LAMCESM, Oujda, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,10]]},"reference":[{"issue":"S1","key":"R1-20250806","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hon.2598","article-title":"Primary central nervous system lymphoma: a curable disease","volume":"37","author":"Batchelor","year":"2019","journal-title":"Hematol Oncol"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijsu.2020.10.034","article-title":"The SCARE 2020 guideline: updating consensus Surgical CAse REport (SCARE) guidelines","volume":"84","author":"Agha","year":"2020","journal-title":"Int J Surg"},{"key":"R3-20250806","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1002\/cncr.30965","article-title":"Diagnosis and management of primary central nervous system lymphoma","volume":"123","author":"Han","year":"2017","journal-title":"Cancer"},{"key":"R4-20250806","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hon.2761","article-title":"On point in primary CNS lymphoma","volume":"38","author":"Tsang","year":"2020","journal-title":"Hematol Oncol"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjh.12938","article-title":"Progress in central nervous system lymphomas","volume":"166","author":"Wang","year":"2014","journal-title":"Br J Haematol"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol"},{"key":"R7-20250806","doi-asserted-by":"crossref","first-page":"rjy189","DOI":"10.1093\/jscr\/rjy189","article-title":"Primary dural lymphoma mimicking meningioma: a clinical and surgical case report","volume":"2018","author":"Ragu\u017e","year":"2018","journal-title":"J Surg Case Rep"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"986.e7","DOI":"10.1016\/j.crad.2018.07.107","article-title":"Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI","volume":"73","author":"Saini","year":"2018","journal-title":"Clin Radiol"},{"key":"R9-20250806","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/aol-20-53","article-title":"Primary central nervous system lymphoma: advances in MRI and PET imaging","volume":"5","author":"Ambady","year":"2021","journal-title":"Ann Lymphoma"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"key":"R11-20250806","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/10428190701370605","article-title":"Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study","volume":"48","author":"Yamanaka","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/hon.2342","article-title":"Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study","volume":"35","author":"Doorduijn","year":"2017","journal-title":"Hematol Oncol"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/cam4.1906","article-title":"High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: a retrospective study from China","volume":"8","author":"Chen","year":"2019","journal-title":"Cancer Med"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","article-title":"Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227","volume":"34","author":"Glass","year":"2016","journal-title":"J Clin Oncol"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/asheducation-2017.1.565","article-title":"Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents","volume":"2017","author":"Ferreri","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/PPO.0000000000000449","article-title":"Central nervous system lymphoma: approach to diagnosis and treatment","volume":"26","author":"Correia","year":"2020","journal-title":"Cancer J"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol"},{"key":"R18-20250806","doi-asserted-by":"crossref","first-page":"100213","DOI":"10.1016\/j.esmoop.2021.100213","article-title":"How we treat primary central nervous system lymphoma","volume":"6","author":"Calimeri","year":"2021","journal-title":"ESMO Open"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:18:17Z","timestamp":1754486297000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000001126","relation":{},"ISSN":["2049-0801"],"issn-type":[{"type":"electronic","value":"2049-0801"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"2023-06-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}